Shelby M. Knoche

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Alaina C. Larson · 5 shared papers, 2021–2024 · strength 0.94
   • Paper Correction: Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by act… DOI 10.1007/s12026-023-09442-9↗
   • Paper Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells. DOI 10.3390/ijms25063211↗
   • Paper Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and … DOI 10.1007/s12026-022-09262-3↗
2. Joyce C. Solheim · 5 shared papers, 2021–2024 · strength 0.94
   • Paper Correction: Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by act… DOI 10.1007/s12026-023-09442-9↗
   • Paper Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells. DOI 10.3390/ijms25063211↗
   • Paper Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and … DOI 10.1007/s12026-022-09262-3↗
3. Brittany J. Poelaert · 2 shared papers, 2021–2022 · strength 0.26
   • Paper The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. DOI 10.1371/journal.pone.0273518↗
   • Paper Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of… DOI 10.3390/cancers13071535↗
4. Jennifer D. Black · 1 shared paper, 2022 · strength 0.15
   • Paper The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. DOI 10.1371/journal.pone.0273518↗
5. Bailee H. Sliker · 1 shared paper, 2022 · strength 0.15
   • Paper The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. DOI 10.1371/journal.pone.0273518↗
6. Madeline T. Olson · 1 shared paper, 2022 · strength 0.15
   • Paper The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. DOI 10.1371/journal.pone.0273518↗
7. Ying Yan · 1 shared paper, 2022 · strength 0.15
   • Paper The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. DOI 10.1371/journal.pone.0273518↗
8. Poomy Pandey · 1 shared paper, 2021 · strength 0.11
   • Paper Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of… DOI 10.3390/cancers13071535↗
9. H. Carlo Maurer · 1 shared paper, 2021 · strength 0.11
   • Paper Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of… DOI 10.3390/cancers13071535↗
10. Parthasarathy Seshacharyulu · 1 shared paper, 2021 · strength 0.11
    • Paper Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of… DOI 10.3390/cancers13071535↗
11. Surinder K. Batra · 1 shared paper, 2021 · strength 0.11
    • Paper Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of… DOI 10.3390/cancers13071535↗
12. Kenneth P. Olive · 1 shared paper, 2021 · strength 0.11
    • Paper Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of… DOI 10.3390/cancers13071535↗
13. Satyanarayana Rachagani · 1 shared paper, 2021 · strength 0.11
    • Paper Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of… DOI 10.3390/cancers13071535↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.